Valneva SE (VALN) Assets Average (2022 - 2026)
Valneva SE (VALN) posted Assets Average of $449.9 million for Q1 2026, down 8.95% sequentially from $494.1 million in Q4 2025, and down 13.61% YoY from $520.8 million in Q1 2025.
Analysis
Valneva SE (VALN) Assets Average (2022 - 2026) Analysis & Trends
Valneva SE has reported Assets Average for 5 years, with the latest figure at $449.9 million in Q1 2026.
- Quarterly Assets Average fell 13.61% year-over-year to $449.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $449.9 million (down 13.61% YoY) and the FY2025 annual result came in at $502.7 million, down 3.21% from the prior year.
- Assets Average fell to $449.9 million in Q1 2026 per VALN's latest filing, from $494.1 million in the prior quarter.
- Over five years, Assets Average peaked at $903.9 million in Q1 2022 and troughed at $449.9 million in Q1 2026.
- A 5-year average of $596.3 million and a median of $534.9 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average retreated 29.91% in 2023, then advanced 3.77% in 2024.
- Over 5 years, Assets Average stood at $668.9 million in 2022, then slipped by 20.64% to $530.8 million in 2023, then gained by 3.77% to $550.8 million in 2024, then retreated by 10.3% to $494.1 million in 2025, then dropped by 8.95% to $449.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $449.9 million, $494.1 million, and $529.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Valneva SE | 580.64 Mn | 439.38 Mn | 1.86 Mn | 443.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 443.42 Mn |
| Mar 31, 2026 | 449.90 Mn |
| Dec 31, 2025 | 494.13 Mn |
| Sep 30, 2025 | 529.50 Mn |
| Jun 30, 2025 | 521.13 Mn |
| Mar 31, 2025 | 520.80 Mn |
| Dec 31, 2024 | 550.84 Mn |
| Sep 30, 2024 | 534.90 Mn |
| Jun 30, 2024 | 524.35 Mn |
| Mar 31, 2024 | 520.63 Mn |
| Dec 31, 2023 | 530.83 Mn |
| Sep 30, 2023 | 578.74 Mn |
| Jun 30, 2023 | 612.05 Mn |
| Mar 31, 2023 | 633.60 Mn |
| Dec 31, 2022 | 668.89 Mn |
| Sep 30, 2022 | 738.79 Mn |
| Jun 30, 2022 | 823.29 Mn |
| Mar 31, 2022 | 903.94 Mn |